NEW ONSET RENAL REPLACEMENT THERAPY IS A PREDICTOR OF COVID-19 ADVERSE OUTCOMES IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE DUE TO TYPE 2 DIABETES MELLITUS - Docquity - Mexico - Brazil

Skip to content

Resources
Company
- About Us
  
  A community of experts and leaders in health tech.
  
  Careers
  
  Come work with us.

Resources
Company
- About Us
  
  A community of experts and leaders in health tech.
  
  Careers
  
  Come work with us.

English
- Portuguese
- Spanish

Resources Type:

Resources Type:

English
- Portuguese
- Spanish

Articles you may like

Effects of Vaccination and Monoclonal Antibodies on the Outcome of Covid-19 in Patients with Haematological Malignancies

Hematology, Oncology

Clinical Course of Covid-19 After Kidney Transplantation

Hematology, Oncology

Latest Updates on SARS-CoV-2 Immunity

Hematology, Oncology

An Italian real-world experience on the use of tixagevimab/cilgavimab prophylaxis in lung transplant patients during the omicron wave

Hematology, Oncology

NEW ONSET RENAL REPLACEMENT THERAPY IS A PREDICTOR OF COVID-19 ADVERSE OUTCOMES IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE DUE TO TYPE 2 DIABETES MELLITUS

Hematology, Oncology

EFFECTIVENESS OF COVID-19 VACCINE IN PATIENTS UNDERGOING HEMODIALYSIS

Hematology, Oncology

ASSOCIATED FACTORS TO CLINICAL OUTCOMES OF COVID-19 AMONG HOSPITALIZED PATIENTS UNDERGOING MAINTENANCE DIALYSIS

Anesthesiology, familymedicine, generalpractitioner, Internalmedicine

Clinical Burden of RSV Disease

Hematology, Oncology

Respiratory viral infections in the elderly population: several clinical presentations and outcomes

Hematology, Oncology

NEW ONSET RENAL REPLACEMENT THERAPY IS A PREDICTOR OF COVID-19 ADVERSE OUTCOMES IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE DUE TO TYPE 2 DIABETES MELLITUS

Hematology, Oncology

Powered by Merck

Articles you may like

Effects of Vaccination and Monoclonal Antibodies on the Outcome of Covid-19 in Patients with Haematological Malignancies

Hematology, Oncology

Clinical Course of Covid-19 After Kidney Transplantation

Powered by Merck

Hematology, Oncology

Latest Updates on SARS-CoV-2 Immunity

Hematology, Oncology

An Italian real-world experience on the use of tixagevimab/cilgavimab prophylaxis in lung transplant patients during the omicron wave

Hematology, Oncology

NEW ONSET RENAL REPLACEMENT THERAPY IS A PREDICTOR OF COVID-19 ADVERSE OUTCOMES IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE DUE TO TYPE 2 DIABETES MELLITUS

Powered by Merck

Hematology, Oncology

EFFECTIVENESS OF COVID-19 VACCINE IN PATIENTS UNDERGOING HEMODIALYSIS

Powered by Merck

Hematology, Oncology

ASSOCIATED FACTORS TO CLINICAL OUTCOMES OF COVID-19 AMONG HOSPITALIZED PATIENTS UNDERGOING MAINTENANCE DIALYSIS

Powered by Merck

Anesthesiology, familymedicine, generalpractitioner, Internalmedicine

Clinical Burden of RSV Disease

Hematology, Oncology

Respiratory viral infections in the elderly population: several clinical presentations and outcomes

Hematology, Oncology

Doctalks you may like

Difference Between Vaccine and mAbs

hematology, oncology

Why Use Monoclonical Antibodies to Prevent Infections?

hematology, oncology

Understanding Where Antibodies Come From

hematology, oncology

Navigating Vulnerability : Unveiling COVID-19’s Impact on High Risk

hematology, oncology

Webinars you may like

Difference Between Vaccines and MABs

hematology, oncology

Why Use Monoclonical Antibodies to Prevent Infections?

hematology, oncology

Understanding Where Antibodies Come From

hematology, oncology

Navigating Vulnerability : Unveiling COVID-19’s Impact on High Risk

hematology, oncology

Company

About Us
Contact Us

About Us
Contact Us

Doctors

Docquity App
Wall of Love

Docquity App
Wall of Love

Resources

Blog

Blog

Newsletter

Subscribe to our newsletter to get the latest news and updates

Email

Based on 15,000+ reviews on

 4.5/5

© 2023 | docquity.com. All rights reserved

Terms & Conditions
Privacy Policy

Terms & Conditions
Privacy Policy

Layanan Pengaduan Konsumen

Docquity Indonesia

WeWork Lim Tower 3, 29A Nguyen Dinh Chieu, Da Kao Ward, District 1, HCMC, Vietnam
For queries: +62 813 1765 2675 (9 AM - 9 PM JKT)

Direktorat Jenderal Perlindungan Konsumen dan Tertib Niaga Kementerian Perdagangan Republik Indonesia

Resources

Company

A community of experts and leaders in health tech.

Come work with us.

English
Portuguese
Spanish

Cookie Consent

We use cookies to improve your browsing experience on our website. By continuing to use our site, you consent to our use of cookies in accordance with our Privacy Policy. You can learn more about how we use cookies in our Privacy Policy.